Reports

Sale

Neovascular Age-Related Macular Degeneration Treatment Market

Neovascular Age-Related Macular Degeneration Treatment Market: By Drug Type: Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab, Faricimab, Others; By Disease Type: Dry AMD, Wet AMD; By Age Group: Less Than 60, Others; By Disease Stage; By Gender; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Neovascular Age-Related Macular Degeneration Treatment Market Outlook

The neovascular age-related macular degeneration treatment market size was valued at USD 11 billion in 2023 in the 7 major markets, driven by the increasing advancements in treatment technologies for neovascular AMD across the globe. The market size is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032 to achieve a value of USD 21.1 billion by 2032.

 

Neovascular Age-Related Macular Degeneration Treatment: Introduction

Neovascular age-related macular degeneration (AMD) treatment are the several therapeutic interventions and strategies that target the progression management this specific form of AMD. Neovascular AMD, also known as wet AMD, is recognized as the growth of abnormal blood vessels beneath the macula, which can lead to severe vision loss if left untreated. The primary purpose of treatment is to slow down or prevent further vision loss and preserve visual function in the patient. The use of anti-vascular endothelial growth factor (anti-VEGF) medications is the most common and effective treatment approach for neovascular AMD. These medications are administered through injections into the eye. These medicines block the growth of abnormal blood vessels and reduce leakage and inflammation in the retina. Examples of anti-VEGF drugs used in neovascular AMD treatment include ranibizumab, aflibercept, and bevacizumab. 

 

Neovascular Age-Related Macular Degeneration Treatment Market Analysis

The increasing prevalence of neovascular AMD globally is mainly due to the geriatric population. With rise in geriatric population, increase in demand for effective treatments for neovascular AMD is expected to increase as well. The market is encountering continuous technological advancements in treatment modalities for neovascular AMD and these advancements are expected to continue in coming years as well contributing to the neovascular age-related macular degeneration treatment market growth. The market expansion is being further fueled by the continuing research and development projects being made to increase treatment efficacy, decrease treatment frequency, and investigate alternative therapies.

 

With increasing awareness of the genetic and molecular factors contributing to neovascular AMD, there is a substantial shift towards personalized medicine across the 7 major markets. Targeted therapies and genetic testing are being explored to identify subgroups of patients who may respond better to specific treatments, allowing for more tailored and effective management accelerating the market growth.

 

Additionally, the integration of digital technologies, such as telemedicine and remote monitoring into neovascular AMD management is being increasing, further contributing to the market growth. Remote monitoring of disease progression and treatment response allows for more efficient patient management, reduces the need for frequent hospital visits, and enhances patient care.

 

Neovascular Age-Related Macular Degeneration Treatment Market Segmentations

Market Breakup by Drug Type

  • Ranibizumab 
  • Aflibercept 
  • Bevacizumab 
  • Brolucizumab 
  • Faricimab 
  • Others 

 

Market Breakup by Disease Type

  • Dry AMD 
  • Wet AMD 

 

Market Breakup by Age Group

  • Less Than 60 
  • Between 60 to 80 
  • More Than 80 

 

Market by Disease Stage

  • Early-Stage AMD 
  • Intermediate Stage AMD 
  • Late-Stage AMD  

 

Market by Gender

  • Male 
  • Female 

 

Market by Distribution Channel 

  • Hospital Pharmacy 
  • Retail Pharmacy 
  • Online Pharmacy 

 

Market Breakup by Region- 7MM

  • United States 
  • EU-4 and the United Kingdom 
    • Germany  
    • France     
    • Italy 
    • Spain 
    • United Kingdom 
  • Japan

 

Neovascular Age-Related Macular Degeneration Treatment Market Overview

The global population is aging, and advanced age is a significant risk factor for neovascular AMD. As the geriatric population continues to grow, the demand for neovascular AMD treatments is expected to increase, furth driving the neovascular age-related macular degeneration treatment market growth. The prevalence of neovascular AMD is also on the rise due to factors such as increasing life expectancy and lifestyle changes among people globally. The rising number of neovascular AMD patients is creating a substantial market demand for effective treatments contributing to the market growth. There have been multiple campaigns to increase awareness against AMD, patient education initiatives, and neovascular AMD screening programs which are substantially improving early detection rates as people. For quick action and the best possible treatment options, neovascular AMD must be identified early and accurately diagnosed. Furthermore, improvements in imaging methods like optical coherence tomography (OCT) and fluorescein angiography are enabling better neovascular AMD diagnosis and monitoring, which is further fuelling the market's need for related treatment choices internationally.

 

Neovascular Age-Related Macular Degeneration Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • F. Hoffmann-La Roche Ltd 
  • Bausch & Lomb  
  • Novartis AG 
  • Pfizer, Inc. 
  • AbbVie Inc. 
  • Santen Pharmaceutical Co., Ltd. 
  • Ophthotech Corporation 
  • Alimera Sciences 
  • GSK plc. 
  • Bayer AG

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Type
  • Disease Type
  • Age Group
  • Disease Stage
  • Gender
  • Distribution Channel
  • Region- 7MM
Breakup by Drug Type
  • Ranibizumab
  • Aflibercept
  • Bevacizumab
  • Brolucizumab
  • Faricimab
  • Others
Breakup by Disease Type
  • Dry AMD
  • Wet AMD
Breakup by Age Group
  • Less Than 60
  • Between 60 to 80
  • More Than 80
Breakup by Disease Stage
  • Early-Stage AMD
  • Intermediate Stage AMD
  • Late-Stage AMD
Breakup by Gender
  • Male
  • Female
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Breakup by Region
  • United States
  • EU-4 and the United Kingdom
  • Japan
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd
  • Bausch & Lomb
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ophthotech Corporation
  • Alimera Sciences
  • GSK plc.
  • Bayer AG

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Neovascular Age-Related Macular Degeneration Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Neovascular Age-Related Macular Degeneration Epidemiology Analysis – 7MM
    5.1    7MM Epidemiology Scenario Overview (2017-2032)
    5.2    United States Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
    5.3    EU-4 and United Kingdom Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
        5.3.1    Germany Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
        5.3.2    France Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
        5.3.3    Italy Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
        5.3.4    Spain Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032)
        5.3.5    United Kingdom Neovascular Age-Related Macular Degeneration Epidemiology Forecast (2017-2032) 
    5.4    Japan Neovascular Age-Related Macular Degeneration Treatment Epidemiology (2017-2032)
6    Neovascular Age-Related Macular Degeneration Treatment Market Overview – 7MM
    6.1    Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023) 
    6.2    Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
7    Neovascular Age-Related Macular Degeneration Treatment Market Landscape – 7MM
    7.1    Neovascular Age-Related Macular Degeneration Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Neovascular Age-Related Macular Degeneration Treatment: Product Landscape
    7.2.1    Analysis by Drug Type
    7.2.2    Analysis by Application
    7.2.3    
8    Neovascular Age-Related Macular Degeneration Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Neovascular Age-Related Macular Degeneration Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Neovascular Age-Related Macular Degeneration Treatment Market Segmentation – 7MM
    11.1    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type
        11.1.1    Market Overview
        11.1.2    Ranibizumab
        11.1.3    Aflibercept
        11.1.4    Bevacizumab
        11.1.5    Brolucizumab
        11.1.6    Faricimab
        11.1.7    Others
    11.2    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
        11.2.1    Market Overview
        11.2.2    Dry AMD
        11.2.3    Wet AMD
    11.3    Neovascular Age-Related Macular Degeneration Treatment Market by Age Group
        11.3.1    Market Overview
        11.3.2    Less Than 60
        11.3.3    Between 60 to 80
        11.3.4    More Than 80
    11.4    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Stage
        11.4.1    Market Overview
        11.4.2    Early-Stage AMD
        11.4.3    Intermediate Stage AMD
        11.4.4    Late-Stage AMD 
    11.5    Neovascular Age-Related Macular Degeneration Treatment Market by Gender
        11.5.1    Market Overview
        11.5.2    Male
        11.5.3    Female
    11.6    Neovascular Age-Related Macular Degeneration Treatment Market by Distribution Channel
        11.6.1    Market Overview
        11.6.2    Hospital Pharmacy
        11.6.3    Retail Pharmacy
        11.6.4    Online Pharmacy
    11.7    Neovascular Age-Related Macular Degeneration Treatment Market by Region
        11.7.1    Market Overview
        11.7.2    United States
        11.7.3    EU-4 and the United Kingdom
            11.7.3.1    Germany 
            11.7.3.2    France    
            11.7.3.3    Italy
            11.7.3.4    Spain
            11.7.3.5    United Kingdom
        11.7.4    Japan
12    United States Neovascular Age-Related Macular Degeneration Treatment Market
    12.1    Neovascular Age-Related Macular Degeneration Treatment Market Historical Size (2017-2023)  
    12.2    Neovascular Age-Related Macular Degeneration Treatment Market Forecast Size (2024-2032)  
    12.3    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type 
    12.4    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
13    EU-4 and United Kingdom Neovascular Age-Related Macular Degeneration Treatment Market 
    13.1    Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023) 
    13.2    Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
    13.3    Germany Neovascular Age-Related Macular Degeneration Treatment Market Overview
        13.3.1    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type 
        13.3.2    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
    13.4    France Neovascular Age-Related Macular Degeneration Treatment Market Overview
        13.4.1    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type 
        13.4.2    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
    13.5    Italy Neovascular Age-Related Macular Degeneration Treatment Market Overview
        13.5.1    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type 
        13.5.2    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
    13.6    Spain Neovascular Age-Related Macular Degeneration Treatment Market Overview
        13.6.1    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type 
        13.6.2    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
    13.7    United Kingdom Neovascular Age-Related Macular Degeneration Treatment Market Overview
        13.7.1    Neovascular Age-Related Macular Degeneration Treatment Market by Drug Type 
        13.7.2    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
14    Japan Neovascular Age-Related Macular Degeneration Treatment Market
    14.1    Neovascular Age-Related Macular Degeneration Treatment Market Historical Value (2017-2023) 
    14.2    Neovascular Age-Related Macular Degeneration Treatment Market Forecast Value (2024-2032)
    14.3    Neovascular Age-Related Macular Degeneration Treatment Market by Disease Type
    14.4    Neovascular Age-Related Macular Degeneration Treatment Market by Treatment Type
15    Regulatory Framework
    15.1    Regulatory Overview
        15.1.1    US FDA
        15.1.2    EU EMA
        15.1.3    JAPAN PMDA
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by Year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization 
18    Clinical Trials Analysis
    18.1     Analysis by Trial Registration Year
    18.2    Analysis by Trial Status
    18.3    Analysis by Trial Phase
    18.4    Analysis by Therapeutic Area
    18.5    Analysis by Geography
19    Funding and Investment Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Supplier Landscape
    21.1    F. Hoffmann-La Roche Ltd
        21.1.1    Financial Analysis
        21.1.2    Product Portfolio
        21.1.3    Demographic Reach and Achievements
        21.1.4    Company News
        21.1.5    Certifications
    21.2    Bausch & Lomb 
        21.2.1    Financial Analysis
        21.2.2    Product Portfolio
        21.2.3    Demographic Reach and Achievements
        21.2.4    Company News
        21.2.5    Certifications
    21.3    Novartis AG
        21.3.1    Financial Analysis
        21.3.2    Product Portfolio
        21.3.3    Demographic Reach and Achievements
        21.3.4    Company News
        21.3.5    Certifications
    21.4    Pfizer, Inc.
        21.4.1    Financial Analysis
        21.4.2    Product Portfolio
        21.4.3    Demographic Reach and Achievements
        21.4.4    Company News
        21.4.5    Certifications
    21.5    AbbVie Inc.
        21.5.1    Financial Analysis
        21.5.2    Product Portfolio
        21.5.3    Demographic Reach and Achievements
        21.5.4    Company News
        21.5.5    Certifications
    21.6    Santen Pharmaceutical Co., Ltd.
        21.6.1    Financial Analysis
        21.6.2    Product Portfolio
        21.6.3    Demographic Reach and Achievements
        21.6.4    Company News
        21.6.5    Certifications
    21.7    Ophthotech Corporation
        21.7.1    Financial Analysis
        21.7.2    Product Portfolio
        21.7.3    Demographic Reach and Achievements
        21.7.4    Company News
        21.7.5    Certifications
    21.8    Alimera Sciences
        21.8.1    Financial Analysis
        21.8.2    Product Portfolio
        21.8.3    Demographic Reach and Achievements
        21.8.4    Company News
        21.8.5    Certifications
    21.9    GSK plc.
        21.9.1    Financial Analysis
        21.9.2    Product Portfolio
        21.9.3    Demographic Reach and Achievements
        21.9.4    Company News
        21.9.5    Certifications
    21.10    Bayer AG
        21.10.1    Financial Analysis
        21.10.2    Product Portfolio
        21.10.3    Demographic Reach and Achievements
        21.10.4    Company News
        21.10.5    Certifications
22    Neovascular Age-Related Macular Degeneration Treatment - Distribution Model (Additional Insight)
    22.1    Overview 
    22.2    Potential Distributors 
    22.3    Key Parameters for Distribution Partner Assessment 
23    Key Opinion Leaders (KOL) Insights (Additional Insight)
24    Company Competitiveness Analysis (Additional Insight)

    24.1    Very Small Companies
    24.2    Small Companies
    24.3    Mid-Sized Companies
    24.4    Large Companies
    24.5    Very Large Companies
25    Payment Methods (Additional Insight)
    25.1    Government Funded
    25.2    Private Insurance
    25.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of about USD 11 billion in 2022, driven by the rising prevalence of neovascular AMD.

The market is anticipated to grow at a CAGR of 7.51% during the forecast period of 2024-2032 and reach a market value of USD 21.1 billion by 2032.

Increasing collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers are contributing to more research and development activities to acquire better treatment solutions for AMD is among the major factors driving the market growth.

The rising emphasis and trials on targeted therapies and genetic testing to identify subgroups of patients who may respond better to specific treatments is among the major trends influencing the market growth.

The 7 major markets for neovascular age-related macular degeneration treatment include United States, EU-4 and the United Kingdom, and Japan. EU-4 includes Germany, France, Italy, and Spain.

The key drugs available in the market are Ranibizumab, Aflibercept, Bevacizumab, Brolucizumab, and Faricimab, among others.

The age groups include people who are less than 60, between 60 to 80, and more than 80.

The disease stages include early-stage AMD, intermediate stage AMD, and late-stage AMD.

On basis of gender, market is segmented into male and female.

The distribution channels include hospital pharmacy, retail pharmacy, and online pharmacy.

Key players involved in the market are F. Hoffmann-La Roche Ltd, Bausch & Lomb, Novartis AG, Pfizer, Inc., AbbVie Inc., Santen Pharmaceutical Co., Ltd., Ophthotech Corporation, Alimera Sciences, GSK plc., and Bayer AG.

Purchase Full Report

Mini Report

$ 3299     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 6599     $5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8799     $7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9899     $8999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER